CORDIS
EU research results

CORDIS

English EN

A Clostridal Biology Network to Facilitate European-wide Medical Countermeasures and Commercial Exploitation

Objective

There is an urgent need to better understand the basic biology of Clostridium as a prerequisite for both countering the diseases they cause (C.difficile, C.perfringens and C.botulinum), and exploiting their beneficial properties in industry (biofuels by C.acetobutylicum) and medicine (cancer therapy by C.sporogenes). Attainment of this goal is being impeded because: (i) European research efforts are fragmented; (ii) there is no coherence between researchers working on pathogenic species and industrially important strains; (iii) there is a demonstrable (SCF-CT-2005-029958) lack of trained young clostridial researchers; (iv) there is inadequate networking between industry and academia, and; (v) effective exploitation of the amassed clostridial genome data has been precluded by a woeful inadequacy in procedures for gene inactivation. Removal of these impediments cannot be achieved at a national level, but requires the creation of a transnational network of multi-disciplinary experts,active in different scientific sectors. The technical hurdle to progress has now been solved by partner 1, who has developed a highly effective andreproducible gene knock-out system. The remaining hurdles will be overcome by bringing together a multidisciplinary team of research expertise from 7 different EU states drawn from Academia (5), Government (3) and different sectors of Industry (3). A principal focus will be to address the deficiency in critical mass by providing young researchers with world class, state-of-the-art, multidisciplinary training in leading scientific and biotechnological skills that have relevance to medical countermeasures against pathogens and the exploitation of non-pathogens in industrial processes and disease intervention. These measures will establish Europe as a ‘Centre of Excellence’ for clostridial research, propelling the community to the forefront of the field, eclipsing the efforts of the rest of the world, and in particular the USA and Japan.

Coordinator

THE UNIVERSITY OF NOTTINGHAM

Address

University Park
Ng7 2rd Nottingham

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 534 256,80

Administrative Contact

Paul Cartledge (Mr.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

THE UNIVERSITY OF EXETER

United Kingdom

EU Contribution

€ 444 925,65

UNIVERSITAET ROSTOCK

Germany

EU Contribution

€ 428 796,63

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 428 796,63

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 453 389,92

ZAVOD ZA ZDRAVSTVENO VARSTVO MARIBOR

Slovenia

EU Contribution

€ 359 073,43

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 428 903,81

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 437 562,92

METABOLIC EXPLORER SA

France

EU Contribution

€ 430 416,47

GLAXOSMITHKLINE VACCINES SRL

Italy

EU Contribution

€ 424 908,42

Phico Therapeutics Ltd

United Kingdom

UNILEVER U.K. CENTRAL RESOURCES LIMITED

United Kingdom

EU Contribution

€ 440 760,32

INTERVET INTERNATIONAL BV

Netherlands

Project information

Grant agreement ID: 237942

Status

Closed project

  • Start date

    1 September 2009

  • End date

    31 August 2013

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 4 811 791

  • EU contribution

    € 4 811 791

Coordinated by:

THE UNIVERSITY OF NOTTINGHAM

United Kingdom